In recent years, there has been much debate over whether marijuana, an illegal drug, can provide patients with a level of therapeutic relief comparable to existing pharmaceutical treatments. While this idea is hardly new, it is advanced by some proponents as deserving more scientific inquiry. Advocates for the medical use of marijuana contend that there is already sufficient scientific evidence to justify rescheduling marijuana under the Controlled Substances Act, a change that would give it the necessary legal recognition to be used for medicinal purposes. This has already occurred in the case of dronabinol, the synthetic form of the main psychoactive ingredient in marijuana, which has been available as an oral prescription drug since 1986 under its brand name Marinol. To address these viewpoints, several comprehensive studies were done in the late 1990s to evaluate medicinal claims made for smoked marijuana and determine whether they are supported by convincing scientific evidence. The medical marijuana debate gained attention at the state level in 1996, when voters in California and Arizona approved ballot initiatives allowing doctors to prescribe the drug for therapeutic uses. In 1998, similar propositions were adopted in Alaska, Nevada, Oregon, and Washington, and reaffirmed in Arizona. Voters in Maine adopted a medical marijuana initiative in 1999. In 2000, medical marijuana was approved by voters in Colorado, reconfirmed in Nevada, and passed by the legislature in Hawaii. Federal health officials assert that these initiatives are part of a strategy to soften the nation's drug laws, and that public policy would be better served if science, rather than the ballot box, were used to judge the drug's utility. This book assesses the current issues and examines the controversies regarding the marijuana legalization issue.
The topic of sexual harassment is a real threat to society in spite of its downplaying by a large segment of society including the 42nd President of the United States. This book presents analyses designed to help shed light on it and a bibliography sorted for ease of use.
Title IV of the Higher Education Act (HEA) authorises the major federal student aid programs, including the student loan programs, which are the largest source of aid for students. In FY2000, the Federal Family Education Loan (FFEL) programs and the Federal Direct Student Loan (DL) program supported an estimated $33.1 billion in new loan volume. Several types of loans are available: Federal need-based subsidised Stafford loans (under which the government pays the interest while the borrower is in school, a grace period of deferment); unsubsidised Stafford loans; Federal PLUS loans (for parents of undergraduate students); and Federal Consolidation loans. Overall, student loan volume has been increased in recent years, from $24 billion in FY1994 to $33 billion in FY2000. The number of loans being made has increased over the same period going from 6,483,000 to 8,618,000. The average amount that individual students are borrowing in any given year has not increased as dramatically. This new book examines important issues related to this cornerstone of American higher education.
This will help us customize your experience to showcase the most relevant content to your age group
Please select from below
Login
Not registered?
Sign up
Already registered?
Success – Your message will goes here
We'd love to hear from you!
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.